Thanks for your post
the reason I’ve been excited lately is because ..
Says it all..
Dr Cathryn M Clary
Chief Medical Advisor
Dr. Cathryn M Clary is an experienced physician and life sciences executive whose career in the pharmaceutical and biotech industry has focused on the development and commercialization of novel therapeutics to meet patient need. She has over 25 years of enterprise leadership experience across R&D, Medical Affairs strategy across multiple therapeutic areas, new indication development, and medical policy and patient engagement strategies.
Dr. Clary was most recently the SVP, Clinical Development and Chief Medical Officer of SalioGen Therapeutics, where she led clinical development, translational medicine, and regulatory strategy. She also served as acting chief medical officer at Solid Biosciences, a gene therapy company focusing on Duchenne Muscular Dystrophy, for over two years from 2020 through 2022. Dr. Clary spent nearly 13 years at Pfizer Inc, where she had numerous roles including VP, Neuroscience and ultimately SVP and Head of US Medical, serving on the US Executive team. She spent 3 years at Ipsen Pharmaceuticals leading their US Clinical Development and Medical Affairs team, and 6 years at Novartis, where she led their US clinical development and medical affairs for General Medicines and oversaw launches of products in the Dermatology/Immunology and Cardiovascular therapeutic areas.
Dr. Clary received Board certification from the American Board of Psychiatry and Neurology. She completed a medical internship and residency in psychiatry at The University of Pennsylvania. A Life Fellow of the American Psychiatric Association, Dr. Clary received a B.A. cum laude in English literature from Bryn Mawr College, an M.D. from The University of Missouri-Columbia School of Medicine and subsequently an M.B.A. degree from the University of Delaware.
- Forums
- ASX - By Stock
- PER
- FDA approves Sareptas Srp901 for the whole population
FDA approves Sareptas Srp901 for the whole population, page-62
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.7¢ |
Change
0.003(3.57%) |
Mkt cap ! $78.43M |
Open | High | Low | Value | Volume |
8.4¢ | 8.7¢ | 8.4¢ | $72.99K | 855.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 452608 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 398595 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 452608 | 0.084 |
3 | 212500 | 0.083 |
2 | 106250 | 0.080 |
2 | 125578 | 0.079 |
1 | 12462 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 398595 | 1 |
0.088 | 400000 | 1 |
0.089 | 135000 | 2 |
0.090 | 794374 | 5 |
0.092 | 50000 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online